ELVN Q3 2021 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$24,000

Operating Income

-$14M

Net Income

-$14M

EPS (Diluted)

$-2.19

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$107M

Total Liabilities

$8M

Stockholders' Equity

$99M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$24,000	$0	—
Operating Income	-$14M	-$12M	-9.3%
Net Income	-$14M	-$12M	-9.9%